Remove tag molecular-biology
article thumbnail

Actualising the power of antibody-drug conjugates as cancer therapeutics

European Pharmaceutical Review

To engineer an ideal ADC, the drug must achieve a cohesive, molecular partnership between the cellular target, antibody, cytotoxic payload and chemical linker. This development was enabled by a constantly evolving understanding of the interplay between the different ADC components and their relationship with disease biology.

article thumbnail

Putting complex medicines under the microscope

European Pharmaceutical Review

Based on fluorescently labelled antibodies and drugs, the technology offers an array of benefits to drug discovery, from characterising complex cell models of disease to understanding the molecular mechanism of drug action. Isabel’s expertise lies in developing microscopy methods to understand cellular molecular mechanism.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CEPI provides $30m to advance novel coronavirus vaccine

European Pharmaceutical Review

Dr Jack Tan, Senior Postdoctoral Scientist at the MRC Weatherall Institute of Molecular Medicine, University of Oxford, added: ?“We These coronavirus RBDs are attached to a nanoparticle by protein tags, enabling the structure to display fragments from multiple viruses on a single nanoparticle. . The innovative protein ?“glue”

article thumbnail

How To Sell Effectively In Diagnostic Testing Sales With Kelly Buber

Evolve Your Success

H e’s sold medical devices, capital equipment, and molecular diagnostic testing as well. We take a look at the tumor biology of that. We pull the molecular data out with our gene expression profile test. Can we get this test done and provide some feedback on what this cancer looks like at a molecular level?”

Sales 52
article thumbnail

Developing point-of-care CAR T manufacturing

European Pharmaceutical Review

Being a cellular therapy that involves cell manipulation and molecular transfection – and above all, being a living drug – makes CAR T-cell therapy a somewhat challenging immunotherapy to manufacture in‑house. This is in addition to its considerable price tag. Sengsayadeth S, Savani BN, Oluwole O, Dholaria B. 2021;3(S1):6–10.